U.S. ‘Must Immediately Invest’ In Efforts To Develop Zika Vaccine

Wall Street Journal: The Coming Trials of Generation Zika
W. Ian Lipkin, professor of epidemiology and director of the Center for Infection and Immunity at Columbia University’s Mailman School of Public Health

“…The question is how large we will allow [Zika’s] impact to be. … The best path forward is a global vaccination program to reduce the impact of Zika here and in the developing world where resources to address the social and economic consequences are even more scarce. Unlike HIV, it will not be difficult to engineer an inexpensive and effective Zika vaccine. … It will take up to $1 billion and two to three years to complete the process of safety and efficacy testing, manufacture, and distribution. This is a nonpartisan challenge that cannot wait until after the November election. We must immediately invest the relatively modest resources needed to prevent our own and future generations from being defined by an infectious agent” (9/6).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.